Epidemiology
PVCs are common with an estimated prevalence of 1% to 4% in the general population. 5 In a normal healthy population, PVCs have been detected in 1% of subjects on standard 12-lead electrocardiography and between 40% and 75% of subjects on 24-to 48-hour Holter monitoring. 6 Their prevalence is generally age-dependent, 1 ranging from Ͻ1% in children Ͻ11 years 7 to 69% in subjects Ͼ75 years. 8 Commonly thought to be a benign entity, 4, 5 the concept of PVC-induced cardiomyopathy was proposed by Duffee et al 9 in 1998 when pharmacological suppression of PVCs in patients with presumed idiopathic dilated cardiomyopathy subsequently improved left ventricular (LV) systolic dysfunction. Many of these patients often have no underlying structural heart disease and subsequently develop LV dysfunction and dilated cardiomyopathy; in cases of those with an already impaired LV function from underlying structural heart disease, worsening of LV function may occur. 10, 11 The exact prevalence of PVC-induced cardiomyopathy is not known; it is an underappreciated cause of LV dysfunction, and it is primarily observed in older patients. 12 This observation could be due to the fact that the prevalence of PVCs increases with age or the possibility that PVC-induced cardiomyopathy develops in a time-dependent fashion. 12 In fact, Niwano et al 13 demonstrated progressive worsening of LV function in patients with frequent PVCs (Ͼ1000 beats/day) as measured by the LV ejection fraction (LVEF) and LV end-diastolic dimension over a follow-up period of 4 to 8 years ( Figure 1 ).
Electrophysiological Characteristics

PVC Burden
Several studies have shown that the frequency of PVCs correlates at least modestly with the extent of LV dysfunction and ventricular dilation at the time of initial clinical presentation. [13] [14] [15] [16] [17] Patients with decreased LVEF had a higher mean PVC burden than their counterparts with normal LV function (29%-37% versus 8%-13%). 15, 18, 19 However, there are no clear-cut points that mark the frequency at which cardiomyopathy is unavoidable. Niwano et al 13 used a cut point of 20 000 PVCs over 24 hours to define the high-frequency group, whereas Kanei et al 17 used a figure of 10 000 PVCs per day. Other studies defined "frequent" PVCs as Ͼ10% of total beats rather than the absolute number of PVCs, 18, 19 yet in some cases, a high PVC burden may not impair LV function, whereas PVC-induced cardiomyopathy can be observed in patients with lower PVC frequencies, albeit at lower incidences. 12, 16, 17 It is not known why the majority of patients with frequent PVCs have a benign course, whereas up to one third of them develop cardiomyopathy. One possible explanation is that the evaluation of PVC burden using 24-hour Holter monitoring may be inadequate and may misrepresent the patient's true PVC burden. 20 Baman et al 18 suggested that a PVC burden of Ͼ24% had a sensitivity and specificity of 79% and 78%, respectively, in separating the patient populations with impaired versus preserved LV function. Nevertheless, the majority of patients presenting with frequent PVCs had preserved LVEF. 4, 9, 12, 13, 15 Therefore, although significant, the PVC burden is not the only factor contributing to impairment of LV systolic function. 9, 15, 21 
PVC Origin
Approximately two thirds of idiopathic PVCs originate from the ventricular outflow tracts, primarily the right ventricular outflow tract. 3, 22 The ventricular outflow tract musculature, and hence the anatomic source of the PVCs, may extend above the pulmonary or aortic valves. Gami et al 23 examined 603 autopsy hearts and found that 57% of these hearts had myocardial extensions above the aortic valve, and 74% had extensions above the pulmonary valve. Extensions were noted more often in the right coronary cusp (55%) than in the left coronary cusp (24%) and noncoronary/posterior cusp (Ͻ1%). In contrast, myocardial extensions above the 3 pulmonary cusps are distributed more evenly (45%-60%). These myocardial extensions constitute the electric substrates for ectopies and tachycardia. The remaining third of PVCs may have various ventricular origins, including the ventricular free walls, LV fascicles, septum, and papillary muscles. These ectopics may originate from single or multiple foci, presenting as monomorphic or polymorphic PVCs on electrocardiography. It should be noted that PVCs originating from the outflow tracts are often monomorphic.
Munoz et al 22 retrospectively studied 70 subjects who underwent PVC ablation. Of these, 17 (24%) had a reduced LVEF Ͻ50%. When compared with those with LVEF of Ն50%, there was no significant difference in baseline patient characteristics except that patients with reduced LVEF were less likely to have reported symptoms. Interestingly, in addition to a higher PVC burden being observed in patients with reduced LVEF, PVCs originating from the right ventricle were associated with significant reduction of LVEF at a PVC burden Ն10%, whereas PVCs originating from the LV were associated with significant reduction of LVEF only at a higher PVC burden of Ն20%. This finding, however, has to be interpreted within the constraints of a retrospective study design with a small sample size and a highly selected population. Whether delayed LV excitation and contraction from right ventricular PVCs pose greater hemodynamic threat to the myocardial function is a question that has not been studied, but it is plausible given the observation of right ventricular pacing-induced LV dysfunction. 24 -29 
PVC QRS Morphology, Duration, Coupling Interval, and Interpolation
Although the threshold burden of PVCs associated with reduced LVEF was lower for right as compared with LV PVCs, data from 1 study suggest that the PVC morphology such as left bundle branch block or right bundle branch block pattern does not appear to affect the LVEF. 22 However, the morphology can, to some extent, determine the site and etiology of the PVCs. PVCs with smooth and uninterrupted contours as well as a sharp QRS deflection typically represent an isolated ectopic focus and a structurally normal heart, whereas PVCs with broad notching and a slurred QRS deflection may represent a diseased myocardial substrate. 30 PVCs originating from the fascicles or ventricular septum typically have a narrower QRS wave as opposed to PVCs originating from the free walls and outflow tracts. One study noted that PVC duration Ն140 ms was an independent predictor of impaired LVEF. 22 There is inconsistent evidence as to whether the coupling interval is associated with LV dysfunction. A study by Sun et al 31 reported that PVC coupling intervals Յ600 ms had a lower mean LVEF. A recent study by Olgun et al 32 showed that PVC interpolation is an independent predictor of PVC-induced cardiomyopathy, although other studies have not corroborated this observation. 22 These observations may not apply to all patients because these are single studies with small numbers of patients. Decreased PVC coupling interval may affect the LV filling profile, stroke volume, and pulse pressure. 33 The association between coupling interval and hemodynamic/ structural consequence remains to be examined.
Mechanisms and Pathophysiology
PVC-induced cardiomyopathy was originally thought to be a type of tachycardia-induced cardiomyopathy, 12,14,15,21 a phenomenon that has been well described in the context of atrial fibrillation, supraventricular tachycardia, and ventricular tachycardia. 12 However, this concept has been called into question because patients with frequent PVCs have overall heart rates similar to those of their normal counterparts on Holter monitoring. 13, 14 The cellular mechanisms of PVCinduced cardiomyopathy have as yet not been elucidated and are only speculative at present given the dearth of animal models and prospective clinical studies in this area. However, on the basis of the observation that some patients with frequent PVCs had isoproterenol-facilitated induction of sustained monomorphic ventricular tachycardia of similar morphologies to the PVCs, 34 Yarlagadda et al 12 postulated that cAMP-mediated triggered activity may be an operative mechanism in some patients with PVCs. Frequent and persistent exposure to PVCs is associated with complex transient alterations in intracellular calcium and membrane ionic currents, heart rate dynamics, hemodynamic parameters, and both myocardial and peripheral vascular autonomic stimulation and inhibition. [35] [36] [37] [38] Morphological and functional abnormalities of the ventricular myocardium and outflow tracts may be found on MRI in patients with apparently idiopathic PVCs, albeit this does not necessarily have a clinical implication. Bogun et al 15 postulated that ventricular dyssynchrony and increased oxygen consumption may be possible patho- Figure 1 . Relationship between the prevalence of premature ventricular contractions (PVCs) and changes in left ventricular ejection fraction (LVEF) and left ventricular end-diastolic dimension (LVEDD) over a 4-year observational period. The ⌬LVEF was calculated as (LVEF at the evaluation time point)Ϫ(initial LVEF) and the ⌬LVEDD was calculated as (LVEDD at the evaluation time point)Ϫ(initial LVEDD); each parameter was plotted against the PVC prevalence for each patient. Although most of the patients exhibited only small changes in LVEF and LVEDD, several patients exhibited a relatively large decrease in the LVEF and increase in the LVEDD. There was a weak but significant negative correlation between the PVC prevalence and ⌬LVEF and a weak but significant positive correlation between the PVC prevalence and ⌬LVEDD at the 4-year follow-up. Adapted from Niwano et al. 13 Used with permission. genic mechanisms. Ventricular dyssynchrony results in compromised global cardiac mechanical efficiency, asymmetrically increased wall thickness in the late-activated regions, altered myocardial blood flow, and local changes in myocardial protein expression. 28 The ventricular dyssynchrony associated with PVCs, particularly when the PVC burden is high, may contribute to LV dilation and impaired function in a fashion previously described for patients with left bundle branch block or chronic right ventricular pacing. [25] [26] [27] [28] [29] Right ventricular pacing is notably associated with dyssynchronous ventricular contraction, 39 changes in cardiac sympathetic activity, histopathology as well as ion channel expression and function 40 ; animal models have shown that right ventricular pacing induces asymmetrical myocardial hypertrophy, myofibrillar disarray, and increased catecholamine concentrations in the myocardium. [41] [42] [43] Although clinical studies describe LV dysfunction developing over reasonably long periods of time (Ͼ4 years in the series of Niwano et al 13 ) , in canine models, LV dysfunction occurred within 4 to 12 weeks of induced ventricular ectopy. 44, 45 However, this PVC-induced cardiomyopathy animal model in a 3-month duration demonstrated the lack of myocardial fibrosis and absence of changes in apoptosis and mitochondrial function, which support a functional rather than structural mechanism. Smith et al 46 observed sympathoexcitation evoked by acutely high rates of ventricular ectopy using programmed ventricular extrastimuli after every 4, 2, and 1 spontaneous sinus beats in patients with a history of supraventricular tachycardia. This inappropriate sympathetic activation could potentially impair LV function in the long-term, yet although animal models are crucial in helping us understand a variety of pathophysiological aspects that are difficult or unable to explore in human subjects, and give us an impression of the relationship between the onset and burden of PVCs to the development of systolic dysfunction, the limited comparability between animal and human studies has to be taken into account. Patient-specific factors such as genetic predispositions determining myocardial protein expression in response to PVC-induced stress may interact with PVC frequency to influence the risk of cardiomyopathy. 47 The putative mechanisms of PVC-induced cardiomyopathy are summarized in Figure 2 .
Clinical Evaluation
In many patients, the onset of frequent PVCs relative to the onset of LV dysfunction is unknown. 47 It is particularly important to identify the primary disorder because of the potential reversibility of PVC-induced cardiomyopathy. 48, 49 Patients can present with debilitating symptoms, particularly palpitations, or other symptoms such as chest pain, presyncope, syncope, or heart failure manifested by decreased effort tolerance, possibly as a result of decreased effective cardiac output. 3 The vast majority of these patients are healthy with no known structural heart disease, 4 but a detailed family history is required to help exclude familial dilated cardiomyopathy. The physical examination findings are often normal except irregular heart rhythm when PVCs are frequent. The electrocardiography may indicate the presence and morphology of PVCs, but PVC burden should be assessed by continuous Holter monitoring for at least 24 hours. Because a single 24-hour recording may not reflect the true PVC load due to day-to-day variability, a strong suspicion that frequent PVCs may be the cause of LV dysfunction may warrant extended Holter recordings of 48 to 72 hours or several 24-hour Holter recordings. 20 Echocardiography is useful to exclude valvular pathology, regional wall motion abnormalities, cardiomyopathies, or myocardial abnormalities such as noncompaction, all of which could be a cause for frequent PVCs. Echocardiographic features in PVC-induced cardiomyopathy include decreased LVEF, increased LV systolic and diastolic dimensions, wall motion abnormalities, which are often global as opposed to regional, 20 as well as mitral regurgitation (typically due to mitral annular dilatation). 14 Two-dimensional speckle tracking strain imaging has shown altered LV contractility, whereas the LVEF remains preserved. 50 -54 Whether the abnormal findings from speckle tracking imaging predict the reduction of LVEF in patients 
Cha et al Premature Ventricular Contractions
with PVCs remains to be studied. Cardiac MRI may be warranted in detecting arrhythmogenic right ventricular cardiomyopathy with LV involvement and infiltrative disease when clinically suspected. Coronary angiography should be performed in every patient with reduced LV systolic function to exclude significant coronary artery disease except for those with a low cardiovascular risk. Appropriate workup should also be performed to exclude other causes of cardiomyopathy, including those related to drugs/toxins, infectious diseases, and endocrinopathies. It should be noted that PVC-induced cardiomyopathy remains a diagnosis of exclusion; underlying structural disease causing frequent PVCs must be ruled out. Given the reciprocal causal association between PVCs and cardiomyopathy where either 1 can lead to the other, it may be difficult to isolate the primary disorder. 49, 55 In many patients, the onset of frequent PVCs relative to the onset of LV dysfunction is unknown. 47 It is particularly important to identify the primary disorder because of the potential reversibility of PVCinduced cardiomyopathy. 48, 49 
Therapeutic Modalities
A therapeutic medical trial or catheter ablation may be considered in patients with LV dysfunction and frequent PVCs (a generally accepted range of Ͼ10 000 -20 000 13, 17 or Ͼ10% of total heart beats 18,19,22 over 24 hours) if the clinical suspicion for PVC-induced cardiomyopathy is high. The patient should be followed up over 3 to 12 months to assess posttreatment PVC frequency as well as LV size and function. The workup, treatment, and follow-up of patients with frequent PVCs are summarized in Figure 3 .
Pharmacological Therapy
Because the long-term prognosis of frequent PVCs is generally considered to be benign and the majority of patients presenting with frequent PVCs have a preserved LVEF, 4, 9, 12, 13, 15 the preferred treatment is usually reassurance and counseling of the patient with close follow-up if the patient is asymptomatic. In the presence of symptoms, pharmacotherapy such as a ␤-blocker or a nondihydropyridine calcium channel blocker may be the first-line therapy. 56 Krittayaphong et al 57 showed, in a randomized placebo-controlled study, that atenolol significantly decreased symptom frequency and PVC count. Antiarrhythmics such as flecainide or sotalol may be considered when ␤-blockers or calcium channel blockers are ineffective. 58 Capucci et al 59 demonstrated that 91% of patients taking flecainide and 55% of patients on mexiletine had a PVC reduction of Ն70%. In the presence of overt LV dysfunction, Class IA or IC drugs such as flecainide or propafenone are not recommended given their side effect profiles, including the propensity for proarrhythmic effects and adverse impact on survival. 3, 60 Careful consideration in regard to the baseline renal and hepatic function is also necessary when initiating an antiarrhythmic agent to avoid inadvertent drug toxicity. Amiodarone and dofetilide are preferred in view of their favorable cardiac safety profile. [61] [62] [63] A randomized, double-blind, placebo-controlled trial conducted by Singh et al 11 showed that amiodarone was significantly more effective in suppressing PVCs with concomitant improvement in LVEF in patients with congestive heart failure and asymptomatic ventricular arrhythmia.
Catheter Ablation
Catheter-based ablative approaches represent an emerging effective and alternative therapy to pharmacological treatment and have been increasingly reported over the past decade. Many studies have documented the improvement in LV function after catheter ablation of frequent PVCs ( Table) . 10 -12,14,16,18,21,54 Yarlagadda et al 12 noted a significant improvement in LVEF to near 60% in all patients with LV dysfunction who underwent successful catheter ablation of their frequent PVCs. Bogun et al 15 documented the normalization of LVEF in 82% of patients who underwent catheter ablation for frequent PVCs and LV systolic dysfunction. Improvement of LVEF was also documented by Sarrazin et al 10 after catheter ablation of frequent PVCs in the setting of prior myocardial infarction. Other studies also found significant reduction in LV end-diastolic dimensions of between 2 and 8 mm, mitral regurgitation by 75%, and New York Heart Association functional class by nearly 1 class. 14, 15, 21 Wijnmaalen et al 54 described a significant improvement in radial, circumferential, and longitudinal strain after catheter ablation in patients with frequent PVCs and preserved LVEF. However, like with any invasive intervention, the risks of catheter ablation (whether endocardial or epicardial) must be balanced against any potential benefits. 56 Major complications occur in approximately 3% of cases, including death, stroke, myocardial infarction, atrioventricular block necessitating permanent pacemaker placement, cardiac perforation with or without pericardial tamponade, pericardial effusion, and blood vessel dissection or stenosis. 64 Nevertheless, catheter ablation for PVCs is associated with a high success rate and few complications. 12, 14, 15, 21, 58 Advancements and innovations in catheter ablation technology have favorably altered the efficacy-safety profile of ablation therapy. Our ability to predict the site of origin of the PVCs on surface electrocardiography 65 and to safely access the right ventricular outflow tract and left ventricle (including the pericardium and the aortic cusp region) 66, 67 and the use of advanced 3-dimensional mapping tools allows us to precisely localize the PVC foci. Short-term ablation success rates of between 70% and 90% have been reported 10, 21, 22, 54 ; however, the long-term ablative outcomes remain to be studied. Alternative energy sources such as cryoablation may help improve the efficacy-safety profile as compared with traditional radiofrequency-based techniques. 68 Given the favorable efficacy-safety profile of current catheter ablation techniques, we believe that catheter ablation is an increasingly appealing therapy for management of patients with suspected PVC-induced cardiomyopathy. However, randomized clinical trials are needed to determine a comparative efficacy and outcome of modern medical against ablative approaches for those with frequent PVCs that are likely to be the cause of cardiomyopathy.
Future Perspectives
Knowledge of the molecular, cellular, and hemodynamic mechanisms of LV dysfunction in PVC-induced cardiomyopathy is limited. Despite the limited comparability between animal models and human subjects, animal models enable us to study the effects of PVCs and to understand the pathogenesis of PVC-induced cardiomyopathy. Development of better imaging techniques such as 2-dimensional speckle tracking strain imaging and cardiac MRI aimed at assessing early LV dysfunction and excluding occult structural heart disease allows the possibility of earlier detection of the disease. There is at present little evidence to recommend the routine use of such imaging techniques in the workup of PVC-induced cardiomyopathy. Although the suppression of PVCs is indicated for symptomatic patients with frequent PVCs and those with overt LV dysfunction, there is at present no evidence for the treatment of asymptomatic patients with normal LVEF to prevent PVC-induced cardiomyopathy. Further research is needed to identify the risk predictors for developing PVCinduced cardiomyopathy and to make a recommendation on the need and frequency of echocardiographic follow-up in this group of patients. In patients with a diagnosis of nonischemic cardiomyopathy and frequent PVCs with uncertainty as to the former being the cause or consequence of the latter, the plausibility of suppressing PVCs with medical or interventional therapy before placement of an implantable cardioverter-defibrillator (if current guidelines for its insertion are met) requires further study, bearing in mind that the cardiomyopathy is potentially reversible. In patients with decreased LVEF, a follow-up period of 3 to 12 months after initiation of antiarrhythmic therapy or catheter ablation is suggested to allow for recovery of LV function and to avoid unnecessary implantable cardioverter-defibrillator insertions in a potentially reversible condition. 11, 14, 15, 18 Where reduced LVEF persists despite diminished PVC burden, the decision as to the need for implantable cardioverter-defibrillator insertion should be governed by current guidelines. 69 Frequent PVCs might be a factor responsible for the lack of response to medical therapy or cardiac resynchronization therapy. Suppression or elimination of PVCs may improve response to cardiac resynchronization therapy.
Conclusions
PVCs are a common occurrence within the general population. In the absence of structural heart disease, they typically carry a good prognosis. However, they may present with debilitating symptoms. PVCs have been implicated in the development of LV dysfunction and cardiomyopathy, but the risk factors and pathogenic mechanisms are incompletely understood. The suppression of PVCs using either antiarrhythmic pharmacological agents or emerging catheter ablation techniques appears to reverse the LV dysfunction. PVCs indicates premature ventricular contractions; LVEF, left ventricular ejection fraction; LBBB, left bundle branch block; LV, left ventricular; RV, right ventricular, LVEDD, left ventricular end-diastolic dimension; MR, mitral regurgitation; NYHA, New York Heart Association; LVESD, left ventricular end-systolic dimension.
